131 related articles for article (PubMed ID: 33410163)
1. Non-small-cell lung cancer infiltrated with chronic myelomonocytic leukaemia: a molecular diagnostic challenge to recognise mixed cancers in a single biopsy.
Koopman B; Hiddinga BI; Platteel I; Kluiver JL; Timens W; Mulder AB; van Doesum JA; Schuuring E; Diepstra A; van Kempen LC
Histopathology; 2021 Jun; 78(7):1043-1046. PubMed ID: 33410163
[No Abstract] [Full Text] [Related]
2. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
3. ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.
Lambros L; Guibourg B; Uguen A
Clin Lung Cancer; 2018 Jan; 19(1):e73-e74. PubMed ID: 28919190
[No Abstract] [Full Text] [Related]
4. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation.
Pruis MA; Paats MS; Geurts WRR; Dubbink HJ; Dingemans AC
JCO Precis Oncol; 2021 Nov; 5():849-853. PubMed ID: 34994615
[No Abstract] [Full Text] [Related]
6. A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
Chen K; Zhang F; Pan G; Sheng J; Ye J; Xu Y; Yu X; Huang Z; Fan Y
Clin Lung Cancer; 2021 Jan; 22(1):e1-e4. PubMed ID: 32778510
[No Abstract] [Full Text] [Related]
7. MET-Mutated NSCLC with Major Response to Crizotinib.
Mendenhall MA; Goldman JW
J Thorac Oncol; 2015 May; 10(5):e33-e34. PubMed ID: 25898965
[No Abstract] [Full Text] [Related]
8. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
Shimokawa M; Nosaki K; Seto T; Ohashi K; Morise M; Horinouchi H; Sakakibara J; Murakami H; Yano S; Satouchi M; Matsumoto S; Goto K; Yoh K
Trials; 2020 Mar; 21(1):298. PubMed ID: 32228679
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Gao J; Li HR; Jin C; Jiang JH; Ding JY
Clin Transl Oncol; 2019 Oct; 21(10):1287-1301. PubMed ID: 30864018
[TBL] [Abstract][Full Text] [Related]
11. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
[TBL] [Abstract][Full Text] [Related]
12. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
13. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
[No Abstract] [Full Text] [Related]
14. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance.
Xu Y; Fan Y
Cancer Biol Ther; 2019; 20(2):145-149. PubMed ID: 30422759
[TBL] [Abstract][Full Text] [Related]
15. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
[TBL] [Abstract][Full Text] [Related]
16. Successful Treatment of a Patient With NSCLC Harboring an EGFR Mutation and a Concomitant Met Exon 14 Skipping Mutation Combining Afatinib and Crizotinib.
Kauffmann-Guerrero D; Kahnert K; Kumbrink J; Syunyaeva Z; Tufman A; Huber RM
Clin Lung Cancer; 2019 Jan; 20(1):59-62. PubMed ID: 30341016
[No Abstract] [Full Text] [Related]
17. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform.
Quinn AM; Hickson N; Adaway M; Priest L; Jaeger E; Udar N; Keeling C; Kamieniorz M; Dive C; Wallace A; Byers RJ; Newman WG; Nonaka D; Blackhall FH
J Thorac Oncol; 2015 May; 10(5):784-792. PubMed ID: 25634010
[TBL] [Abstract][Full Text] [Related]
19. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
20. Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib.
Berger LA; Janning M; Velthaus JL; Ben-Batalla I; Schatz S; Falk M; Iglauer P; Simon R; Cao R; Forcato C; Manaresi N; Bramlett K; Buson G; Hanssen A; Tiemann M; Sauter G; Bokemeyer C; Riethdorf S; Reck M; Pantel K; Wikman H; Loges S
J Thorac Oncol; 2018 Dec; 13(12):e243-e246. PubMed ID: 30205165
[No Abstract] [Full Text] [Related]
[Next] [New Search]
